1
|
Paller AS, Green LJ, Silverberg N, Stripling S, Cartwright M, Enloe C, Wells N, Kowalewski EK, Maeda-Chubachi T. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis. Pediatr Dermatol 2024; 41:438-444. [PMID: 38413239 DOI: 10.1111/pde.15575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Accepted: 02/13/2024] [Indexed: 02/29/2024]
Abstract
OBJECTIVE Controlling molluscum contagiosum (MC) infections is critical in atopic dermatitis (AD) management. This post hoc analysis assessed the efficacy and safety of berdazimer gel, 10.3% (topical, antiviral, nitric oxide-releasing medication) versus vehicle in MC patients with or without AD. METHODS Three Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group trials (B-SIMPLE[berdazimer sodium in molluscum patients with lesions]1, -2, -4) enrolled patients 6 months and older with 3-70 mollusca. Berdazimer or vehicle was applied once daily to all MC lesions for 12 weeks. Data from three Phase 3 studies were integrated for subgroup efficacy and safety assessments using several weighted meta-analysis approaches. Patients with concurrent AD or a history of AD/eczema were categorized as AD+ subgroup (AD- when absent). Primary efficacy endpoint: complete lesion clearance at Week 12. Safety endpoints included adverse events (AEs) through Week 24 and local skin reactions through Week 12. RESULTS Of 1598 enrolled patients, 209 (13.1%) were AD+. Baseline mean lesion counts were greater in AD+ (26.4) than AD- (19.3). Complete clearance rates were higher at Week 12 for berdazimer compared with vehicle in AD+ (n = 209; 35.0% vs. 27.4%; odds ratio [OR], 1.3; 95% CI, 0.7-2.5) and AD- (n = 1389; 29.1% vs. 18.9%; OR 1.8; 95% CI 1.4-2.4) subgroups. AEs in AD+ were application-site pain (21.6% with berdazimer vs. 11.9% with vehicle), dermatitis (12.8% vs. 2.4%), and erythema (9.6% vs. 7.1%). CONCLUSIONS Berdazimer gel showed favorable efficacy regardless of AD status. Berdazimer-induced erythema may be indistinguishable from AD symptoms or with inflammatory response upon resolution of molluscum.
Collapse
Affiliation(s)
- Amy S Paller
- Department of Dermatology, Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, USA
| | - Lawrence J Green
- Department of Dermatology, George Washington University School of Medicine, Washington, DC, USA
| | - Nanette Silverberg
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Stephen Stripling
- Pediatric Department, Coastal Pediatric Research, Charleston, South Carolina, USA
| | | | | | | | - Elaine Kearney Kowalewski
- Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
| | | |
Collapse
|
2
|
Luo Z, Yin F, Wang X, Kong L. Progress in approved drugs from natural product resources. Chin J Nat Med 2024; 22:195-211. [PMID: 38553188 DOI: 10.1016/s1875-5364(24)60582-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Indexed: 04/02/2024]
Abstract
Natural products (NPs) have consistently played a pivotal role in pharmaceutical research, exerting profound impacts on the treatment of human diseases. A significant proportion of approved molecular entity drugs are either directly derived from NPs or indirectly through modifications of NPs. This review presents an overview of NP drugs recently approved in China, the United States, and other countries, spanning various disease categories, including cancers, cardiovascular and cerebrovascular diseases, central nervous system disorders, and infectious diseases. The article provides a succinct introduction to the origin, activity, development process, approval details, and mechanism of action of these NP drugs.
Collapse
Affiliation(s)
- Zhongwen Luo
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
| | - Fucheng Yin
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
| | - Xiaobing Wang
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
| | - Lingyi Kong
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
| |
Collapse
|
3
|
Sugarman JL, Hebert A, Browning JC, Paller AS, Stripling S, Green LJ, Cartwright M, Enloe C, Wells N, Maeda-Chubachi T. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol 2024; 90:299-308. [PMID: 37804936 DOI: 10.1016/j.jaad.2023.09.066] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 09/05/2023] [Accepted: 09/19/2023] [Indexed: 10/09/2023]
Abstract
BACKGROUND An out-of-office therapeutic agent indicated for molluscum contagiosum is needed. OBJECTIVE To assess the efficacy and safety of berdazimer gel, 10.3% (a topical, antiviral, nitric oxide-releasing medication) versus vehicle. METHODS Berdazimer gel, 10.3% or vehicle was applied once daily to all molluscum contagiosum lesions for 12 weeks in patients ≥6 months with 3-70 mollusca. Efficacy assessment: complete lesion clearance and partial clearance at week 12. Safety and tolerability assessment: adverse events through week 24 and local skin reactions through week 12. RESULTS There were 1598 patients enrolled (n = 917 berdazimer, n = 681 vehicle). Berdazimer was superior to vehicle at week 12 in complete clearance rates, 30.0% versus 19.8% (odds ratio, 1.75; 95% CI, 1.38-2.23, P < .001). Subgroup analyses of primary efficacy showed consistent favorable efficacy for berdazimer across most subgroups, including age, sex, baseline lesion count, and disease duration. Berdazimer provided favorable outcome for partial clearance. Application-site pain (18.7% vs 4.8% in berdazimer vs vehicle) and erythema (11.7% vs 1.3%), mostly mild to moderate, were the most common local skin reactions. LIMITATIONS Berdazimer sodium in molluscum patients with lesions (B-SIMPLE) trials enrolled only US patients; no efficacy assessments beyond week 12. CONCLUSIONS Berdazimer gel, 10.3% showed favorable efficacy and safety across subgroups.
Collapse
Affiliation(s)
- Jeffrey L Sugarman
- Department of Dermatology, University of California San Francisco, San Francisco, California
| | - Adelaide Hebert
- Department of Dermatology, UTHealth McGovern Medical School, Houston, Texas
| | | | - Amy S Paller
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Stephen Stripling
- Pediatric Department, Coastal Pediatric Research, Charleston, South Carolina
| | - Lawrence J Green
- Department of Dermatology, George Washington University School of Medicine, Washington, DC
| | | | | | - Nick Wells
- Syneos Health, Hampshire, United Kingdom
| | | |
Collapse
|
4
|
Keam SJ. Cantharidin Topical Solution 0.7%: First Approval. Paediatr Drugs 2024; 26:95-100. [PMID: 38007409 DOI: 10.1007/s40272-023-00600-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2023]
Abstract
Cantharidin (YCANTH™) is a proprietary drug-device combination product containing a formulation of cantharidin 0.7% topical solution (a vesicant naturally derived from blister beetles) delivered via a single-use applicator that has been developed by Verrica Pharmaceuticals Inc. for the treatment of molluscum contagiosum and is also being developed for the treatment of warts. In July 2023, YCANTH™ (cantharidin 0.7% topical solution) was approved for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older in the USA. This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
Collapse
Affiliation(s)
- Susan J Keam
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
| |
Collapse
|
5
|
Browning JC, Cartwright M, Thorla I, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results. Am J Clin Dermatol 2023; 24:119-133. [PMID: 36287306 PMCID: PMC9870829 DOI: 10.1007/s40257-022-00733-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/27/2022] [Indexed: 01/27/2023]
Abstract
BACKGROUND Molluscum contagiosum is often characterized by persistent lesions and bothersome symptomology. What patients with molluscum contagiosum and/or caregivers consider to be meaningful measures of therapeutic success is unknown. OBJECTIVE We aimed to collect patient experience data and assess Global Impression of Change from patients and/or caregivers participating in a large phase III molluscum contagiosum interventional trial. METHODS The Berdazimer Sodium In Molluscum Patients with LEsions (B-SIMPLE4) phase III study enrolled 891 patients with molluscum contagiosum. Patients were randomly assigned to berdazimer gel, 10.3% or vehicle gel applied once daily for 12 weeks. Assessments of participant and investigator perceptions of complete lesion clearance were collected at weeks 12 and 24 along with Global Impression of Change scores from 1 (very much improved) to 7 (very much worse). A subset of 30 B-SIMPLE4 patients participated in the patient/caregiver experience exit interview to evaluate bothersome signs and symptoms. RESULTS At week 12, among participants with a ≥ 75% molluscum contagiosum lesion count reduction from baseline (as assessed by investigators), 99% (373/376) reported improvement. Perceptions of complete clearance at week 12 were nearly 40% for both participant-reported and investigator-reported Global Impression of Change in berdazimer group vs 20% in the vehicle group: 82% (322/392) of participants in the berdazimer group and 60% (237/394) in the vehicle group reported their molluscum contagiosum lesions were either very much improved or much improved at week 12. Similarly, investigators scored 80% (314/393) of berdazimer and 54% (215/396) of vehicle participants as very much improved or much improved. From the exit interview, the mean duration of participant-reported molluscum contagiosum was nearly 2 years. The most frequently reported molluscum contagiosum-related signs and symptoms were itch (n = 20), scarring (n = 18), and pain (n = 13). Visibility and contagiousness of molluscum contagiosum were the most bothersome aspects to participants. The most frequently reported psychosocial impacts were self-consciousness (n = 15) and embarrassment (n = 14). Lesion clearance was an expectation of 28/30 study participants. Overall, 26/30 reported being very satisfied (n = 18) or satisfied (n = 8) with the changes in their disease over the duration of the trial; 23/30 stated that the change in lesion count was meaningful. A mean reduction of 18 lesions (76% decrease) from the baseline lesion count was reported by participants (n = 28). Although 22 of 28 had less than complete lesion clearance, 17 of 22 reported that the reduction in the number of lesions was meaningful. CONCLUSIONS Molluscum contagiosum lesion reductions, with or without complete clearance, may be considered a therapeutic "success" by the patient/caregiver. CLINICAL TRIAL REGISTRATION NCT04535531 (registered 2 September, 2020).
Collapse
Affiliation(s)
- John Caleb Browning
- Department of Dermatology, University of Texas Health Science Center, San Antonio, TX, USA
| | - Martina Cartwright
- Medical Affairs, Novan, Inc., 4020 Stirrup Creek Drive, Suite 110, Durham, NC, 27703, USA
| | - Ira Thorla
- Dermatology, DelRicht Research, Baton Rouge, LA, USA
| | - Susan A Martin
- Patient-Centered Outcomes Assessment, RTI Health Solutions, Ann Arbor, MI, USA
| | | | - Tomoko Maeda-Chubachi
- Medical Affairs, Novan, Inc., 4020 Stirrup Creek Drive, Suite 110, Durham, NC, 27703, USA.
| |
Collapse
|
6
|
Lacarrubba F, Micali G, Trecarichi AC, Quattrocchi E, Monfrecola G, Verzì AE. New Developing Treatments for Molluscum Contagiosum. Dermatol Ther (Heidelb) 2022; 12:2669-2678. [PMID: 36239905 PMCID: PMC9674806 DOI: 10.1007/s13555-022-00826-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 09/27/2022] [Indexed: 11/28/2022] Open
Abstract
A large variety of treatments for molluscum contagiosum (MC) are available, but none are Food and Drug Administration (FDA) approved and there is no consensus on the optimal approach, mainly owing to a lack of high-level data. Physical modalities are widely used, but require repeated outpatient visits for administration, are painful and difficult to perform in children, and are associated with the possibility of residual scarring and post-inflammatory hypo- or hyperpigmentation. Two experimental topical drugs, a new standardized preparation of topical cantharidin, called VP-102, and a topical nitric oxide (NO)-releasing product containing berdazimer, called SB206, represent promising products that have been designed to overcome the limitations of current treatments. They have recently shown good results in terms of safety and efficacy in large cohorts of patients in phase III studies and have the potential to be the first FDA-approved therapies for the treatment of MC.
Collapse
Affiliation(s)
- Francesco Lacarrubba
- Dermatology Clinic, University of Catania, Via S. Sofia 78, 95123, Catania, Italy.
| | - Giuseppe Micali
- Dermatology Clinic, University of Catania, Via S. Sofia 78, 95123, Catania, Italy
| | | | | | - Giuseppe Monfrecola
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Anna Elisa Verzì
- Dermatology Clinic, University of Catania, Via S. Sofia 78, 95123, Catania, Italy
| |
Collapse
|
7
|
Affiliation(s)
- Vikash S Oza
- The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York
| |
Collapse
|
8
|
Browning JC, Enloe C, Cartwright M, Hebert A, Paller AS, Hebert D, Kowalewski EK, Maeda-Chubachi T. Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2022; 158:871-878. [PMID: 35830173 PMCID: PMC9280611 DOI: 10.1001/jamadermatol.2022.2721] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Molluscum contagiosum (MC) is a highly contagious skin condition. Lesions may persist for months to years, and no US Food and Drug Administration-approved medications are currently available in the US. Objective To assess the efficacy and safety of berdazimer gel, 10.3%, a novel topical nitric oxide-releasing medication, in the treatment of MC. Design, Setting, and Participants This was a multicenter, vehicle-controlled, double-blind, phase 3 randomized clinical trial (B-SIMPLE4) conducted in 55 clinics (mostly dermatology and pediatric) in the US from September 1, 2020, to July 21, 2021. Eligible participants were 6 months or older and had from 3 to 70 raised MC lesions. Patients with sexually transmitted MC or with MC only in the periocular area were excluded. Interventions Patients were randomized to treatment with berdazimer gel, 10.3%, or vehicle gel, applied as a thin layer to all lesions once daily for 12 weeks. Main Outcomes and Measures The primary efficacy end point was complete clearance of all MC lesions at week 12. Safety and tolerability measures included adverse event frequency and severity, and assessment of local skin reactions and scarring. Data analyses were performed from August 31, 2021, to September 14, 2021. Results A total of 891 participants were randomized, 444 to berdazimer, 10.3% (mean [range] age, 6.6 [0.9-47.5] years; 228 [51.4%] male; 387 [87.2%] White individuals), and 447 to vehicle (mean [range] age, 6.5 [1.3-49.0] years; 234 [52.3%] female; 382 [85.5%] White individuals). In the intention-to-treat population, 88.5% (393 patients) in the berdazimer group and 88.8% (397 patients) in the vehicle group had a lesion count performed at week 12. At week 12, 32.4% (144 patients) in the berdazimer group achieved complete clearance of MC lesions compared with 19.7% (88 patients) in the vehicle group (absolute difference, 12.7%; odds ratio, 2.0; 95% CI, 1.5-2.8; P < .001) with 14.4% (64 patients) of the berdazimer group discontinuing treatment because of MC clearance compared with 8.9% (40 patients) of the vehicle group. Adverse event rates were low. The most common adverse events were application-site pain and erythema, mostly mild in severity. Adverse events leading to discontinuation affected 4.1% (18 patients) of the berdazimer group and 0.7% (3 patients) of the vehicle group. The most common local skin reaction was mild to moderate erythema. Conclusions and Relevance Use of berdazimer gel, 10.3%, for MC appears to demonstrate favorable efficacy and safety with low adverse event rates. Trial Registration ClinicalTrials.gov Identifier: NCT04535531.
Collapse
Affiliation(s)
| | | | | | - Adelaide Hebert
- University of Texas Health McGovern Medical School, Houston, Texas
| | - Amy S Paller
- The Feinberg School of Medicine of Northwestern University, Chicago, Illinois
| | - David Hebert
- Novan Inc, Durham, North Carolina.,Radius Health Inc, Boston, Massachusetts
| | | | | |
Collapse
|
9
|
Phan S, Wyant C, Huynh C, Joaquin C, Hassan O. Efficacy of topical treatments for molluscum contagiosum in randomized controlled trials. Clin Dermatol 2021; 39:1005-1013. [PMID: 34920817 DOI: 10.1016/j.clindermatol.2021.07.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Although molluscum contagiosum (MC) is a common infectious dermatosis that is self-resolving, treatment can diminish discomfort and decrease the risk of autoinoculation and infection to others, because it is transmitted through direct skin contact. This systematic review evaluates the efficacy of topical treatments for MC. A PubMed search following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was performed to find randomized, controlled trials of MC treatment. The search yielded 129 publications, but only 15 studies published between 1994 and 2020 were found to fit the inclusion criteria. Treatment modalities included podophyllotoxin, imiquimod, sodium nitrite, myrtle leaf extract, phenol, Salatac Gel (salicylic acid with lactic acid), potassium hydroxide, cantharidin, SB206, and VP-102. Outcomes were extracted from the literature, and subsequent quality and risk of bias assessments were performed. All treatments were more efficacious than the control except cantharidin, potassium hydroxide, and imiquimod, which had varying degrees of efficacy throughout studies. Overall, studies were of sufficient quality and had low risk of bias, but they had small sample sizes and lacked adequate explanation of statistical analysis. Current first-line treatment entails mechanical methods such as cryotherapy and curettage, which may be frightening to children with MC, so the development and assessment of topical treatments allows for alternative efficacious techniques.
Collapse
Affiliation(s)
- Sheshanna Phan
- Department of Basic Sciences, Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada, USA.
| | - Cara Wyant
- Department of Basic Sciences, Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada, USA
| | - Christy Huynh
- Department of Basic Sciences, Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada, USA
| | - Christian Joaquin
- Department of Clinical Education, Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania, USA
| | - Omron Hassan
- Department of Basic Sciences, Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada, USA
| |
Collapse
|
10
|
Guenthner S, McFalda W, Tate M, Eads K, Rieger J, Glover DK, Willson C, Rumney P, Rosen T, Andres J, Olivadoti M. Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. Am J Clin Dermatol 2021; 22:867-875. [PMID: 34515985 PMCID: PMC8436872 DOI: 10.1007/s40257-021-00635-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/26/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND External genital warts are caused by various subtypes of the human papilloma virus and spread through direct skin-to-skin contact. Approximately 1% of the US population have external genital warts. Although cantharidin has been used to treat external genital warts for decades, there are no US Food and Drug Administration-approved cantharidin products and no reliable or controlled sources of cantharidin available. VP-102 is a drug-device combination product containing cantharidin (0.7% w/v) in a single-use shelf-stable applicator. OBJECTIVE The objective of this randomized, double-blind, vehicle-controlled, phase II clinical trial was to determine the optimal regimen for the treatment, safety, and efficacy of VP-102 in external genital warts. METHODS The study was conducted in two parts. Part A was dose finding and Part B was performed following the completion of Part A for a safety and efficacy evaluation. Following completion of Part A, 6-h and 24-h VP-102 regimens under occlusion were selected to be evaluated in Part B. RESULTS Pooled results from Part B and Part A of the 6-h and 24-h VP-102 treatment regimens showed that 36.7% and 33.3% of participants achieved complete clearance of all treatable external genital warts at the end of treatment vs 4.2% (p < 0.0048) and 0% (p < 0.0075) with the vehicle. Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity. The most common adverse events included application-site vesicles, pain, and erythema. No participants discontinued the study because of adverse events and no serious adverse events were deemed treatment related. CONCLUSIONS The adverse event profile and efficacy of VP-102 under occlusion demonstrated in this study support the conclusion that a 6-h or up to 24-h exposure regimen represents an acceptable risk:benefit profile and justifies the conduct of a larger vehicle-controlled phase III study in external genital warts. CLINICAL TRIAL REGISTRATION NCT03981822, actual study start date: 25 June, 2019; actual primary completion date: 21 May, 2020; actual study completion date: 8 July, 2020.
Collapse
Affiliation(s)
| | | | | | - Kimberly Eads
- The Indiana Clinical Trials Center, Plainfield, IN, USA
| | | | | | - Cynthia Willson
- Verrica Pharmaceuticals Inc., 44 West Gay Street, Suite 400, West Chester, PA, 19380, USA
| | - Pamela Rumney
- Verrica Pharmaceuticals Inc., 44 West Gay Street, Suite 400, West Chester, PA, 19380, USA
| | - Ted Rosen
- Baylor College of Medicine, Houston, TX, USA
| | - Jennifer Andres
- Verrica Pharmaceuticals Inc., 44 West Gay Street, Suite 400, West Chester, PA, 19380, USA.
| | - Melissa Olivadoti
- Verrica Pharmaceuticals Inc., 44 West Gay Street, Suite 400, West Chester, PA, 19380, USA
| |
Collapse
|
11
|
Eichenfield LF, Kwong P, Gonzalez ME, Yan A, D'Arnaud P, Burnett P, Olivadoti M. Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials. THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY 2021; 14:42-47. [PMID: 34976290 PMCID: PMC8711618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
TRIAL REGISTRATION >ClinicalTrials.gov identifier nos. NCT03377790 (for CAMP-1) and NCT03377803 (for CAMP-2). BACKGROUND VP-102 is drug-device combination product containing cantharidin (0.7% w/v) and has undergone Phase III clinical trials for the treatment of molluscum contagiosum (molluscum). Efficacy and safety may differ by body region due to variable skin anatomy. OBJECTIVE We investigated the pooled safety and efficacy of VP-102 by affected body region. METHODS Individuals at least two years of age with molluscum were randomized to topical VP-102 or vehicle once every 21 days until clear (maximum of four applications). Participants were assigned to body region groups where lesions were present at baseline. Body region lesion counts were recorded at each visit. Efficacy was measured by the percentage of participants with complete clearance of lesions by region. Pre-specified adverse events (AEs) were analyzed for those treated in the region on that visit. RESULTS Participants had a mean of two regions affected at baseline. Complete clearance was significantly higher in the VP-102-treated group than with vehicle application in all regions at the last visit (P<0.01 for each region). The incidence of pre-specified AEs was consistent across regions. However, these analyses were post hoc, and individual lesions were not tracked for efficacy. CONCLUSION VP-102 treatment shows consistent safety and efficacy across molluscum body regions.
Collapse
Affiliation(s)
- Lawrence F Eichenfield
- Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California
- Dr. Kwong is with Solutions Through Advanced Research in Jacksonville, Florida
- Dr. Gonzalez is with the University of Miami Medical School in Miami, Florida
- Dr. Yan is with the Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Philadelphia in Philadelphia, Pennsylvania
- Mr. D'Arnaud is with Instat Consulting Inc. in Chatham, New Jersey
- Drs. Burnett and Olivadoti are former employees of Verrica Pharmaceuticals Inc. in West Chester, Pennsylvania
| | - Pearl Kwong
- Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California
- Dr. Kwong is with Solutions Through Advanced Research in Jacksonville, Florida
- Dr. Gonzalez is with the University of Miami Medical School in Miami, Florida
- Dr. Yan is with the Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Philadelphia in Philadelphia, Pennsylvania
- Mr. D'Arnaud is with Instat Consulting Inc. in Chatham, New Jersey
- Drs. Burnett and Olivadoti are former employees of Verrica Pharmaceuticals Inc. in West Chester, Pennsylvania
| | - Mercedes E Gonzalez
- Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California
- Dr. Kwong is with Solutions Through Advanced Research in Jacksonville, Florida
- Dr. Gonzalez is with the University of Miami Medical School in Miami, Florida
- Dr. Yan is with the Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Philadelphia in Philadelphia, Pennsylvania
- Mr. D'Arnaud is with Instat Consulting Inc. in Chatham, New Jersey
- Drs. Burnett and Olivadoti are former employees of Verrica Pharmaceuticals Inc. in West Chester, Pennsylvania
| | - Albert Yan
- Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California
- Dr. Kwong is with Solutions Through Advanced Research in Jacksonville, Florida
- Dr. Gonzalez is with the University of Miami Medical School in Miami, Florida
- Dr. Yan is with the Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Philadelphia in Philadelphia, Pennsylvania
- Mr. D'Arnaud is with Instat Consulting Inc. in Chatham, New Jersey
- Drs. Burnett and Olivadoti are former employees of Verrica Pharmaceuticals Inc. in West Chester, Pennsylvania
| | - Pieter D'Arnaud
- Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California
- Dr. Kwong is with Solutions Through Advanced Research in Jacksonville, Florida
- Dr. Gonzalez is with the University of Miami Medical School in Miami, Florida
- Dr. Yan is with the Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Philadelphia in Philadelphia, Pennsylvania
- Mr. D'Arnaud is with Instat Consulting Inc. in Chatham, New Jersey
- Drs. Burnett and Olivadoti are former employees of Verrica Pharmaceuticals Inc. in West Chester, Pennsylvania
| | - Patrick Burnett
- Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California
- Dr. Kwong is with Solutions Through Advanced Research in Jacksonville, Florida
- Dr. Gonzalez is with the University of Miami Medical School in Miami, Florida
- Dr. Yan is with the Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Philadelphia in Philadelphia, Pennsylvania
- Mr. D'Arnaud is with Instat Consulting Inc. in Chatham, New Jersey
- Drs. Burnett and Olivadoti are former employees of Verrica Pharmaceuticals Inc. in West Chester, Pennsylvania
| | - Melissa Olivadoti
- Dr. Eichenfield is with Rady Children's Hospital and the University of California, San Diego, Medical School in San Diego, California
- Dr. Kwong is with Solutions Through Advanced Research in Jacksonville, Florida
- Dr. Gonzalez is with the University of Miami Medical School in Miami, Florida
- Dr. Yan is with the Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Philadelphia in Philadelphia, Pennsylvania
- Mr. D'Arnaud is with Instat Consulting Inc. in Chatham, New Jersey
- Drs. Burnett and Olivadoti are former employees of Verrica Pharmaceuticals Inc. in West Chester, Pennsylvania
| |
Collapse
|
12
|
COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts. Dermatol Ther (Heidelb) 2021; 11:1623-1634. [PMID: 34286459 PMCID: PMC8484407 DOI: 10.1007/s13555-021-00576-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 07/01/2021] [Indexed: 11/29/2022] Open
Abstract
Introduction Verrucae vulgaris, or common warts, is a common skin condition for which there is no US Food and Drug Administration-approved treatment. Compounded cantharidin has been used to treat warts for years but lacks a controlled formulation, consistent application schedule and methods, and robust safety and efficacy studies. VP-102 is a proprietary drug-device combination product containing a topical formulation of 0.7% (w/v) cantharidin in a single-use delivery device. This objective of the phase 2 study was to evaluate the efficacy, safety, tolerability, and optimal regimen of VP-102 in the treatment of common warts. Methods In this open-label trial, participants aged ≥ 2 years with one to six common warts were administered VP-102 topically to treatable common warts once every 14 days (Cohort 1) or once every 21 days in conjunction with paring (Cohort 2), for up to four treatments. Participants were evaluated through to day 84 (Cohort 1) or day 147 (Cohort 2). The primary endpoint was the percentage of participants with complete clearance of all treatable common warts (baseline and new) at day 84. Secondary endpoints included percentage of participants achieving complete clearance of all treatable common warts at other visits. Safety assessments included treatment-emergent adverse events (TEAEs), including local skin reactions (LSRs). Results A total of 21 and 35 participants were enrolled in Cohort 1 and Cohort 2, respectively. Complete clearance at day 84 was seen in 19.0% of participants in Cohort 1 and 51.4% of those in Cohort 2. The most common TEAEs were expected LSRs and included application site vesicles, pain, pruritus, erythema, and scab. Most LSRs were mild or moderate in severity. Conclusion VP-102 showed efficacy in complete clearance of common warts from baseline to day 84, as well as at follow-up visits. Due to the higher percentage of patients exhibiting complete clearance in Cohort 2, the treatment regimen of Cohort 2 will be pursued in future studies. TEAEs were expected due to the pharmacodynamic action of cantharidin, a vesicant. Clinical Trials ID: NCT03487549
Collapse
|
13
|
Eichenfield LF, Siegfried E, Kwong P, McBride M, Rieger J, Glover D, Willson C, Davidson M, Burnett P, Olivadoti M. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol 2021; 22:257-265. [PMID: 33599960 PMCID: PMC7973914 DOI: 10.1007/s40257-020-00570-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2020] [Indexed: 10/26/2022]
Abstract
BACKGROUND Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy. VP-102 is a shelf-stable drug-device combination product that contains topical cantharidin (0.7% weight/volume [w/v]) and is being evaluated for the treatment of molluscum. OBJECTIVES Our objective was to present pooled safety and efficacy analyses of VP-102 in the treatment of molluscum compared with vehicle. METHODS Participants aged ≥ 2 years were randomized 3:2 to topical administration of VP-102 or vehicle in two randomized, double-blind, vehicle-controlled phase III trials. Study drug was applied to all baseline and new lesions once every 21 days until clear or for a maximum of four applications. Assessors blinded to treatment counted all lesions at each study visit. All adverse events (AEs) were documented. Data were pooled for analyses. RESULTS In total, 310 participants received VP-102 and 218 received vehicle. Mean age was 7.5 years (range 2-60) for VP-102 and 6.8 (2-54) for vehicle. Complete clearance of all molluscum lesions at day 84 occurred in 50% of VP-102 participants and 15.6% of vehicle recipients (p < 0.0001). Mean molluscum lesion counts decreased 76% for VP-102 and 0.3% for vehicle at day 84 (p < 0.0001). The most common AEs in the VP-102 group were application site blistering, pruritus, pain, and erythema, which were generally mild or moderate in severity. CONCLUSIONS Pooled analyses showed a significantly higher percentage of participants with complete molluscum lesion clearance and larger reductions in lesion counts with VP-102 than with vehicle. AEs were anticipated because of the pharmacodynamic properties of cantharidin. TRIAL REGISTRATION ClinicalTrials.gov identifiers: NCT03377790 (first posted 19 December 2017) and NCT03377803 (first posted 19 December 2017). Video abstract: Pooled Results of Two Randomized Phase III Trials Evaluating VP 102, a Drug Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum (MP4 131293 KB).
Collapse
|